A Phase 2, Multicenter, Single-Arm Trial of CV301 in Combination With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Atezolizumab (Primary) ; CV 301 (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- Sponsors Bavarian Nordic
- 18 Sep 2018 According to a Bavarian Nordic media release, first patient has been dosed in this study.
- 18 Sep 2018 Status changed from not yet recruiting to recruiting, according to a Bavarian Nordic media release.
- 09 Aug 2018 Status changed from planning to not yet recruiting.